Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Kiniksa Pharmaceuticals stock (KNSA)

Buy Kiniksa Pharmaceuticals stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Kiniksa Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $27.59 – an increase of 2.99% over the previous week. Kiniksa Pharmaceuticals employs 297 staff and has a trailing 12-month revenue of around $338.9 million.

Our top picks for where to buy Kiniksa Pharmaceuticals stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

How to buy Kiniksa Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – KNSA. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Kiniksa Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Kiniksa Pharmaceuticals stock price (NASDAQ: KNSA)

Use our graph to track the performance of KNSA stocks over time.

Kiniksa Pharmaceuticals shares at a glance

Information last updated 2024-10-24.
Latest market close$27.59
52-week range$14.12 - $27.92
50-day moving average $25.64
200-day moving average $21.40
Wall St. target price$34.20
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-0.15

Is it a good time to buy Kiniksa Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kiniksa Pharmaceuticals price performance over time

Historical closes compared with the close of $27.44 from 2024-10-25

1 week (2024-10-22) 2.43%
1 month (2024-09-27) 9.76%
3 months (2024-07-29) 4.97%
6 months (2024-04-29) 47.92%
1 year (2023-10-27) 79.93%
2 years (2022-10-28) 134.13%
3 years (2021-10-29) 164.10%
5 years (2019-10-29) 295.96%

Kiniksa Pharmaceuticals financials

Revenue TTM $338.9 million
Gross profit TTM $173.2 million
Return on assets TTM -3.35%
Return on equity TTM -2.42%
Profit margin -3.02%
Book value $6.12
Market Capitalization $1.9 billion

TTM: trailing 12 months

Kiniksa Pharmaceuticals share dividends

We're not expecting Kiniksa Pharmaceuticals to pay a dividend over the next 12 months.

Have Kiniksa Pharmaceuticals's shares ever split?

Kiniksa Pharmaceuticals's shares were split on 27 June 2024 .

Kiniksa Pharmaceuticals share price volatility

Over the last 12 months, Kiniksa Pharmaceuticals's shares have ranged in value from as little as $14.12 up to $27.92. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiniksa Pharmaceuticals's is 0.32. This would suggest that Kiniksa Pharmaceuticals's shares are less volatile than average (for this exchange).

Kiniksa Pharmaceuticals overview

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom. .

Frequently asked questions

What percentage of Kiniksa Pharmaceuticals is owned by insiders or institutions?
Currently 4.249% of Kiniksa Pharmaceuticals shares are held by insiders and 89.96% by institutions.
How many people work for Kiniksa Pharmaceuticals?
Latest data suggests 297 work at Kiniksa Pharmaceuticals.
When does the fiscal year end for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals's fiscal year ends in December.
Where is Kiniksa Pharmaceuticals based?
Kiniksa Pharmaceuticals's address is: 23 Old Bond Street, London, United Kingdom, WIS 4PZ
What is Kiniksa Pharmaceuticals's ISIN number?
Kiniksa Pharmaceuticals's international securities identification number is: BMG5269C1010
What is Kiniksa Pharmaceuticals's CUSIP number?
Kiniksa Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: G5269C101

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site